Gladiator Giant says prostate cancer blood test could save lives
Gladiators star Jamie Christian has said there are no 'warning signs' for prostate cancer and has urged men to take a blood test that 'could save their life' if diagnosed early.
Known as Giant on the hit BBC show, the bodybuilder has been raising money for Prostate Cancer UK and took part in The Big Golf Race where he played 72 holes of golf and walked more than 26 miles in a single day, completing the challenge in just under 15 hours.
This comes after his uncle, Colin Tomlinson, was diagnosed and later recovered from prostate cancer eight years ago.
View this post on Instagram
A post shared by Jamie Christian (@akathegiant)
Speaking during Men's Health Week, which runs from June 9-15, he said: 'That was just a true example of it can happen to anyone, no matter how fit or healthy you are there are no warning signs for this.
'If people aren't getting the necessary checks, then it could be too late.'
Around one in eight men in the UK will get prostate cancer in their lifetime, according to Prostate Cancer UK.
It occurs when cells in the prostate start to grow in an uncontrolled way with the risk of spreading if not detected early.
One cancer screening is a PSA blood test which checks the level of prostate specific antigens in the blood and, if high, may be a sign of a prostate condition, according to the NHS website.
He said: 'By doing a simple blood test, by going to your GP and having a simple blood test to check your PSA levels, that's like the first step, and it's something really, really easy.
'It could save their life.
View this post on Instagram
A post shared by Jamie Christian (@akathegiant)
'I think men, being men, we're very private individuals especially with certain body parts. So I think the stigma attached to prostate cancer is that men have to go to the doctors and have the prostate exam with the finger up the bum, without being too graphic. I think that puts a lot of people off.
'Having the knowledge of a simple blood test will give you all you need to know that is far, far more beneficial than surely finding out one day that you might have cancer.'
Because prostate cancer often does not have any symptoms, it is important to get checked especially for men over the age of 50, black men and men with a family history of prostate cancer who are at higher risk.
Christian added: 'It's much more powerful to prevent something than to have to cure it, because the cure isn't something that we can have full control over, but prevention-wise, that is in our control to go and get the necessary checks to look after our lifestyle, our diets, our activities, shall we say.
'When you put it like that, a few minutes of your day, why would you not go and do it? Peace of mind.'
The Big Golf Race is the biggest golf fundraising challenge in the UK which encourages participants to choose from the Half Marathon (36 holes and approximately 13 miles of walking), the Marathon (72 holes and over 26 miles), or the Ultra Marathon (100 holes in one day and 35 miles) to raise money and awareness for the charity.
Speaking about the sport Christian added: '(The golf course) is a great place where men can be in a safe space and talk to one another. And these conversations on a golf course are private and respected.
'I think the more people that come on board, the more people that listen, more people that talk, more people that go out and play a game of golf and have those conversations with each other, the better.
'And hopefully, the rates of the actual deaths from prostate cancer will start to fall.'
Christian is best known as Giant on the sports and entertainment show Gladiators which sees professional athletes take on contestants as they try to complete physical challenges.
Prior to being a Gladiator, he was the tallest professional bodybuilder in the world at six feet five and consumed up to 10,000 calories a day. He has since reduced his intake to around 5,000 calories.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
FILAMENT HEALTH ANNOUNCES AUTHORIZATION OF PHASE 2 CLINICAL TRIAL STUDYING BOTANICAL PSILOCYBIN FOR PROLONGED GRIEF DISORDER
The clinical trial at Linkoping University will study Filament's botanical psilocybin drug candidate, PEX010 VANCOUVER, BC, June 11, 2025 /CNW/ - Filament Health Corp. (OTC: FLHLF) ("Filament" or the "Company"), a clinical‐stage natural psychedelic drug development company, today announced that the Swedish Ethical Review Authority and the Swedish Medical Products Agency have authorized a double-blind phase 2 clinical trial studying its botanical psilocybin drug candidate, PEX010, at Linkoping University. The trial will be the first to study the effects of psilocybin in the treatment of prolonged grief disorder. "In an aging society where people may outlive their family members by decades, it is crucial to develop treatment options for those with prolonged grief disorder," said Dr. Rebecca Böhme, Associate Professor at the Linkoping Center for Social and Affective Neuroscience. "This trial will assess whether psilocybin can improve adaptation to the loss experience. We are grateful to Filament Health for facilitating this research." People with prolonged grief disorder are at a 20 percent increased mortality risk. Previous psychological research suggests that the loss of a close person affects self-identity, an aspect of the higher cognitive self. Psilocybin is suggested to cause a transient shift from reliance on prior experiences towards current sensations. The clinical trial at Linkoping University will utilize this shift combined with a self-touch intervention to support re-learning about the bodily self in a trial population of 120 individuals. "We're pleased to provide PEX010 to Linkoping University for this much-needed area of research," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "This will be the ninth European clinical trial to study our drug candidate, positioning Filament as the region's leading supplier of GMP psilocybin." The trial at Linkoping University is expected to begin dosing in Q3 2025. PEX010 is authorized for investigation in 52 clinical trials worldwide for 14 mental health indications. ABOUT FILAMENT HEALTH (OTC:FLHLF)Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on Twitter, Instagram, and LinkedIn. FORWARD LOOKING INFORMATIONCertain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws. SOURCE Filament Health Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Opinion: Stop harassing Canadian drinkers
By David Clement Sen. Patrick Brazeau, who wrestled publicly with the demons of alcohol and emerged recovered and sober, has now set his regulatory sights on the substance he's shaken. His tale of redemption certainly stirs the heart. But he now seeks to impose the lessons he has drawn from his personal experiences on the rest of us. His twin bills, S-202 and S-203, would require cancer warning labels on every bottle of booze and banish alcohol promotion entirely. Not merely misguided, they are a nanny-state sermon dressed up as public health policy. Bill S-202 would require that every can of beer and bottle of Pinot bear warnings about cancer. Echoing the flawed claims of the Canadian Centre for Substance Use and Addiction (CCSA), the senator insists that alcohol is a 'group 1 carcinogen' with 'no safe level' of consumption. This is the kind of linguistic sleight-of-hand that thrives in the neo-prohibitionist mindset, conflating hazard with risk as if the mere possibility of harm were a death sentence. Saying there is 'no safe level' of alcohol is as fatuous as saying there is 'no safe level' of swimming or driving or sex. After all, each has been known to cause injury or death. But existence itself is a gamble and the human condition does not bend, and shouldn't, to absolutist rhetoric. In fact, one of the experts behind this 'no safe level' dogma has since backtracked, admitting on a BBC podcast that the phrase is more alarmist than accurate. The CCSA's own data, which Sen. Brazeau wields like a trump card, reveals the absurdity of his crusade. For a man consuming two drinks a day, the absolute increase in colorectal cancer risk is 0.0028 per cent — three one-thousandths of a per cent. Add up the risks for all cancers cited — liver, esophagus, larynx and so forth — and the total increase for our two-drink male is 0.0099 per cent — one one-hundredths of a per cent. For women, factoring in breast cancer, the figure is 0.0088 per cent. These are not numbers that scream 'public health crisis.' They are statistical whispers, barely audible in a world full of risks. Plastering cancer warnings on alcohol as if it were equivalent to tobacco sows panic where proportion is required. A regular smoker, for example, increases his risk of lung cancer by 2,400 per cent. Equating the two dangers, one a tiny fraction of a per cent and the other thousands of times larger, insults the intelligence of the drinking public and erodes the very credibility of health warnings. If the senator's goal is truly to arm consumers with facts, why not mandate labels proclaiming that for men two drinks a week may lower the risk of ischemic heart disease, which kills more Canadians every year than all the cancers cited by the CCSA combined? Why not cite the peer-reviewed studies — dating back to 1986 and confirmed in at least eight subsequent inquiries — that trace the 'J-curve,' an arc showing that moderate drinkers (one to two drinks daily) enjoy lower mortality rates than teetotallers? Why not also acknowledge the social virtues of a shared pint, and how alcohol, as anthropology and common sense attest, can knit communities together? If truth is the aim, let the labels show benefits as well as costs. But, no, the senator prefers a moralizing monotone that trusts neither citizen nor science. For its part, Bill S-203, would ban all alcohol advertising: print, digital, outdoor, even the fleeting glimpse of a beer logo in a movie or video game. Event sponsorships, point-of-sale displays, all gone. Again the senator draws a false equivalence with tobacco, ignoring the great difference in harm. The deeper question is: by what right does the state presume to shield adults from the promotion of a legal product? Especially one that if consumed in moderation carries very little risk at all. If the aim is to protect children from alcohol's attractions, fine, let's have that debate. But to infantilize adults as if they were incapable of navigating a billboard or a bar display is an affront to liberty itself. William Watson: Do good pipelines make good nations? Opinion: Will Canadians buy the pre-fab housing Ottawa wants to sell them? Sen. Brazeau's bills are a triumph of zeal over reason. They infantilize, exaggerate and disempower. The senator deserves congratulation and admiration for having conquered his own demons, but he has no mandate to exorcise anyone else's. David Clement is North American affairs manager at the Consumer Choice Center. Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
BeOne Medicines to Host Investor R&D Day Webcast on June 26, 2025
SAN CARLOS, Calif., June 11, 2025--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will host an Investor R&D Day in New York City and via webcast on June 26, 2025 at 8:30 am ET. John V. Oyler, Co-Founder, Chairman, and CEO of BeOne, along with the Company's leadership team and distinguished key opinion leaders, will provide an update on BeOne's extensive global innovation pipeline and platforms, including new assets, targets and clinical data, and will share insights on the Company's vision, differentiated capabilities, and value creation drivers. Live webcast of this event can be accessed from the investors section of the Company's website at To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company's website. About BeOne Medicines BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit and follow us on LinkedIn, X, Facebook and Instagram. Forward-Looking Statements This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne's plans, commitments, aspirations and goals related to BeOne's medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the U.S. Securities and Exchange Commission ("SEC") as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the SEC. All information in this presentation is as of the date presented, and BeiGene undertakes no duty to update such information unless required by law. View source version on Contacts Investors: Liza Heapes+1 857-302-5663ir@ Media: Kyle Blankenship+1 667-351-5176media@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data